RetinalGenix Technologies Inc

RetinalGenix Technologies Inc has a negative equity position of -$2.3 million and a current ratio of 0.01, indicating severe liquidity constraints. The company's free cash flow is -$2.43 million, and its operating cash flow is -$558,350, both of which are negative and suggest a lack of cash generation capacity. The company's return on equity is 1.05, which is positive but misleading due to the negative equity base. Its return on assets is -115.43, far below the industry median for biotechnology firms, indicating poor asset utilization and profitability. The debt-to-equity ratio is -0.02, which is also distorted by the negative equity position. RetinalGenix does not report revenue, and its operating income is -$2.42 million, reflecting a lack of commercial operations. The company is entirely dependent on research and development activities, with no disclosed revenue-generating segments. Its geographic exposure is not specified, but the company is incorporated in the United States. The company's growth trajectory is uncertain, as it has not generated revenue and is operating at a loss. The outlook for the current fiscal year does not include any revenue growth, and the next fiscal year is expected to remain in a loss-making position. The company's product candidates, RTG-2023 and RTG-2024, are in development but have not yet reached commercialization. The company faces significant liquidity risk, with a negative net cash position after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. Recent events include the filing of the 10-K for the fiscal year ending December 31, 2023, which outlines the company's financial position and ongoing research activities. There are no recent earnings calls or investor presentations that provide additional insight into the company's strategic direction.